The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics

Oncologist

Volumn 18, Issue 2, 2013, Pages 221-231

  Scott, Jessica M ^a   Lakoski, Susan ^b   Mackey, John R ^c   Douglas, Pamela S ^d   Haykowsky, Mark J ^c   Jones, Lee W ^d  

^a UNIVERSITIES SPACE RESEARCH ASSOCIATION   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiotoxicity; Exercise; Molecular therapeutics; Solid malignancies

Indexed keywords

AXITINIB; BEVACIZUMAB; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; INTERLEUKIN 6; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; NEU DIFFERENTIATION FACTOR; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN;

AEROBIC EXERCISE; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CARDIOTOXICITY; CELL PROLIFERATION; HEART EJECTION FRACTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; EXERCISE; HEART DISEASES; HUMANS; NEOPLASMS; RECEPTOR, ERBB-2;

EID: 84874349671     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0226     Document Type: Review

References (141)

1. Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008; 118:84-95.
2. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-344.
3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53:2231-2247.
4. Force T, Kerkela R. Cardiotoxicity of the new cancer therapeutics: Mechanisms of, and approaches to, the problem. Drug Discov Today 2008; 13:778-784.
5. Jones LW, Haykowsky MJ, Swartz JJ et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-1441.
6. Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology. Clin Chem Lab Med 2011; 49:1937-1948.
7. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121-129.
8. Khouri M, Douglas P, Mackey J et al. Cancer therapy-induced cardiac toxicity in early breast cancer: Addressing the unresolved issues. Circulation 2012 (in press).
9. Neet K, Hunter T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1996;1: 147-169.
10. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-225.
11. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997;1333: F217-248.
12. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-727.
13. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
14. Stephens P, Hunter C, Bignell G et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-526.
15. Lee JW, Soung YH, Seo SH et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12: 57-61.
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
17. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-1283.
18. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
19. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354.
20. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2: 127-137.
21. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310.
22. Arnal-Estape A, Tarragona M, Morales M et al. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res 2010;70:9927-9936.
23. Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460-2468.
24. Dave B, Migliaccio I, Gutierrez MC et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011;29:166-173.
25. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-465.
26. Ky B, Kimmel SE, Safa RN et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009; 120:310-317.
27. Gordon LI, Burke MA, Singh AT et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009;284: 2080-2087.
28. Brero A, Ramella R, Fitou A et al. Neuregulin1beta1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc Res 88:443-452.
29. Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res 2009;315:627-637.
30. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006;41:228-235.
31. Liu X, Gu X, Li Z et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006;48:1438-1447.
32. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129.
33. Kakkar R, Lee RT. Intramyocardial fibroblast myocyte communication. Circ Res 2010;106:47-57.
34. Bostrom P, Mann N, Wu J et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010; 143:1072-1083.
35. Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009;138: 257-270.
36. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: Implications for therapy of heart failure. Circulation 2007;116:954-960.
37. Lemmens K, Segers VF, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 2006;281:19469-19477.
38. Esch BT, Scott JM, Warburton DE et al. Left ventricular torsion and untwisting during exercise in heart transplant recipients. J Physiol 2009;587: 2375-2386.
39. Fernandes T, Hashimoto NY, Magalhaes FC et al. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7). Hypertension 2011;58: 182-189.
40. Lebrasseur NK, Cote GM, Miller TA et al. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Am J Physiol Cell Physiol 2003;284:C1149-1155.
41. McMullen JR, Shioi T, Zhang L et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 2003;100:12355-12360.
42. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007;34: 255-262.
43. Yoon YS, Uchida S, Masuo O et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: Restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005;111:2073-2085.
44. Zhang KR, Liu HT, Zhang HF et al. Long-term aerobic exercise protects the heart against ischemia/reperfusion injury via PI3 kinase-dependent and Akt-mediated mechanism. Apoptosis 2007;12: 1579-1588.
45. McMullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA2007;104:612-617.
46. Kikuchi K, Holdway JE, Werdich AA et al. Primary contribution to zebrafish heart regeneration by gata4() cardiomyocytes. Nature 2010;464: 601-605.
47. Haykowsky MJ, Mackey JR, Thompson RB et al. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res 2009;15:4963-4967.
48. Haykowsky MJ, Liang Y, Pechter D et al. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: The benefit depends on the type of training performed. J Am Coll Cardiol 2007;49:2329-2336.
49. Wisloff U, Stoylen A, Loennechen JP et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: A randomized study. Circulation 2007;115:3086-3094.
50. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
51. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-2049.
52. Munoz-Chapuli R, Quesada AR, Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2004;61:2224-2243.
53. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-7142.
54. Choueiri TK, Mayer EL, Je Y et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29: 632-638.
55. Gerber HP, Hillan KJ, Ryan AM et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-1159.
56. Olfert IM, Howlett RA, Tang K et al. Musclespecific VEGF deficiency greatly reduces exercise endurance in mice. J Physiol 2009;587:1755-1767.
57. Giordano FJ, Gerber HP, Williams SP et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001;98:5780-5785.
58. Lambrechts D, Carmeliet P. Genetics in zebrafish, mice, and humans to dissect congenital heart disease: Insights in the role of VEGF. Curr Top Dev Biol 2004;62:189-224.
59. Chen K, Bai H, Arzigian M et al. Endothelial cells regulate cardiomyocyte development from embryonic stem cells. J Cell Biochem 2010;111:29-39.
60. Dimmeler S, Fleming I, Fisslthaler B et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399: 601-605.
61. Chen Y, Amende I, Hampton TG et al. Vascular endothelial growth factor promotes cardiomyocyte differentiation of embryonic stem cells. Am J Physiol Heart Circ Physiol 2006;291:H1653-1658.
62. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019.
63. Facemire CS, Nixon AB, Griffiths R et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652-658.
64. Izumiya Y, Shiojima I, Sato K et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006;47:887-893.
65. Jain M, Townsend RR. Chemotherapy agents and hypertension: A focus on angiogenesis blockade. Curr Hypertens Rep 2007;9:320-328.
66. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988;35(suppl 5):1-5.
67. Brucks S, Little WC, Chao T et al. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 2005;95:603-606.
68. Iemitsu M, Maeda S, Jesmin S et al. Exercise training improves aging-induced downregulation of VEGF angiogenic signaling cascade in hearts. Am J Physiol Heart Circ Physiol 2006;291:H1290-1298.
69. Wu G, Rana JS, Wykrzykowska J et al. Exerciseinduced expression of VEGF and salvation of myocardium in the early stage of myocardial infarction. Am J Physiol Heart Circ Physiol 2009;296:H389-395.
70. Arany Z, Foo SY, Ma Y et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008; 451:1008-1012.
71. Lin J, Wu H, Tarr PT et al. Transcriptional coactivator PGC-1 alpha drives the formation of slowtwitch muscle fibres. Nature 2002;418:797-801.
72. Laufs U, Werner N, Link A et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004;109:220-226.
73. Mobius-Winkler S, Hilberg T, Menzel K et al. Time-dependent mobilization of circulating progenitor cells during strenuous exercise in healthy individuals. J Appl Physiol 2009;107:1943-1950.
74. Schobersberger W, Hobisch-Hagen P, Fries D et al. Increase in immune activation, vascular endothelial growth factor and erythropoietin after an ultramarathon run at moderate altitude. Immunobiology 2000;201:611-620.
75. Takahashi T, Kalka C, Masuda H et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-438.
76. Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
77. Urbich C, Heeschen C, Aicher A et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005;11:206-213.
78. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
79. Fan Y, Ye J, Shen F et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008;28:90-98.
80. Kolwicz SC, MacDonnell SM, Kendrick ZV et al. Voluntary wheel running and pacing-induced dysfunction in hypertension. Clin Exp Hypertens 2008; 30:565-573.
81. Cohen T, Nahari D, Cerem LW et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-741.
82. Kunisada K, Hirota H, Fujio Y et al. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation 1996;94:2626-2632.
83. Hilfiker-Kleiner D, Hilfiker A, Fuchs M et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004;95:187-195.
84. Kunisada K, Negoro S, Tone E et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci U S A 2000;97:315-319.
85. Trenerry MK, Carey KA, Ward AC, Cameron-Smith D. STAT3 signaling is activated in human skeletal muscle following acute resistance exercise. J Appl Physiol 2007;102:1483-1489.
86. Toth KG, McKay BR, De Lisio M et al. IL-6 induced STAT3 signalling is associated with the proliferation of human muscle satellite cells following acute muscle damage. PLoS One 2011;6:e17392.
87. Hoch M, Fischer P, Stapel B et al. Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell 2011;9:131-143.
88. Westenbrink BD, Ruifrok WP, Voors AA et al. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res 2010;87: 30-39.
89. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23: 7811-7819.
90. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
91. Baselga J, Cortés J, Kim S, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
92. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
93. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
94. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
95. Smith KL, Dang C, Seidman AD. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 2006;5:619-629.
96. Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-2171.
97. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83: 679-686.
98. Ross HJ, Blumenschein GR, Jr. Aisner J et al. Randomized phase II multicenter trial of two schedules of lapatinib as firstor second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010;16: 1938-1949.
99. Slamon D, Gomez HL, Kabbinavar FF et al. Randomized study of pazopanib lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008; 26(15 suppl):1016.
100. Portera CC, Walshe JM, Rosing DR et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14:2710-2716.
101. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-1144.
102. Lenihan D, Suter T, Brammer M et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012;23:791-800.
103. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
104. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
105. Miller K, O'Neill A, Perez E et al. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Ann Oncol 2012;23:331-337.
106. Bear HD, Tang G, Rastogi P et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011;29(15 suppl):1005.
107. Yardley DA, Hart L, Waterhouse DM et al. Preliminary safety results: Addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer. Cancer Res 2009;69(suppl 2): Abstract 4107.
108. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-1260.
109. Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27:3385-3390.
110. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab. Anticancer Res 2007;27:3465-3470.
111. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28:780-787.
112. Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112:2500-2508.
113. Barrios CH, Liu MC, Lee SC et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121:121-131.
114. Bergh J, Greil R, Voytko N et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010;28(18 suppl):1010.
115. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204-5212.
116. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target? The Oncologist 2010;15:130-141.
117. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
118. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
119. Wu S, Chen JJ, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008;9:117-123.
120. Taylor SK, Chia S, Dent S et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital phase II consortium. The Oncologist2010;15: 810-818.
121. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
122. Alberts SR, Fitch TR, Kim GP et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol 2012;35:329-333.
123. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28:2817-2823.
124. Hyams DM, de Oliveira C, Snyder R et al. Cediranib in combination with fulvestrant in hormonesensitive metastatic breast cancer: A phase II randomized study. Cancer Res 2009;69(suppl 24): Abstract 204.
125. Natale RB, Thongprasert S, Greco FA et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-smallcell lung cancer. J Clin Oncol 2011;29:1059-1066.
126. Horti J, Widmark A, Stenzl A et al. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 2009;24:175-180.
127. de Boer RH, Arrieta O, Yang CH et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 2011;29:1067-1074.
128. Martin M, Roche H, Pinter T et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011;12:369-376.
129. Rugo HS, Stopeck AT, Joy AA et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011;29:2459-2465.
130. Kindler HL, Ioka T, Richel DJ et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 2011;12:256-262.
131. Koch LG, Britton SL, Barbato JC et al. Phenotypic differences in cardiovascular regulation in inbred rat models of aerobic capacity. Physiol Genomics 1999;1:63-69.
132. Barbato JC, Koch LG, Darvish A et al. Spectrum of aerobic endurance running performance in eleven inbred strains of rats. J Appl Physiol 1998;85:530-536.
133. Konhilas JP, Maass AH, Luckey SW et al. Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ Physiol 2004;287:H2768-2776.
134. Kemi OJ, Loennechen JP, Wisloff U, Ellingsen O. Intensity-controlled treadmill running in mice: Cardiac and skeletal muscle hypertrophy. J Appl Physiol 2002;93:1301-1309.
135. Wisloff U, Helgerud J, Kemi OJ, Ellingsen O. Intensity-controlled treadmill running in rats: VO(2 max) and cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2001;280:H1301-1310.
136. Hooning MJ, Botma A, Aleman BM et al. Longtermriskofcardiovasculardiseasein10-yearsurvivors of breast cancer. J Natl Cancer Inst 2007;99:365-375.
137. Wang Y, Wisloff U, Kemi OJ. Animal models in the study of exercise-induced cardiac hypertrophy. Physiol Res 2010;59:633-644.
138. Scott JM, Khakoo A, Mackey JR et al. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: Current evidence and underlying mechanisms. Circulation 2011;124: 642-650.
139. Brunello A, Roma A, Falci C, Basso U. Chemotherapy and targeted agents for elderly women with advanced breast cancer. Recent Pat Anticancer Drug Discov 2008;3:187-201.
140. Jones LW, Liang Y, Pituskin EN et al. Effect of exercise training on peak oxygen consumption in patients with cancer: A meta-analysis. The Oncologist 2011;16:112-120.
141. Betof AS, Dewhirst MW, Jones LW. Effects and potential mechanisms of exercise training on cancer progression: A translational perspective. Brain Behav Immun 2012 [Epub ahead of print].